iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
In the United States, the FDA-approved gene therapy LUXTURNA is for a specific group: people with confirmed biallelic RPE65 mutation-associated retinal dystrophy who also have viable retinal cells. “Retinal prosthetic goggles” usually refers to Argus II, an implanted device system that is no longer available. Its historical eligibility criteria were narrow; a different system called Orion is investigational and not FDA-approved, according to its manufacturer.
Who may qualify for LUXTURNA gene therapy?
The FDA indication is for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. “Biallelic” means disease-causing variants are present in both copies of the RPE65 gene. A diagnosis of inherited retinal disease or blindness by itself is not enough: the indication is gene-specific, not a general treatment for inherited blindness.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
CafePress Retinal Implant, Artwork Round 4" MDF Holiday Ornament | $8.99 | Buy on Amazon |
Genetic confirmation is only one part of assessment. The FDA orphan-drug record says the patient must also have viable retinal cells, as determined by the treating physician. A retinal specialist and genetics team can interpret the test result alongside the eye examination and determine whether the labeled criteria fit the individual.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsAge and diagnosis need individual interpretation
The LUXTURNA label says treatment is not recommended for children younger than 12 months because retinal cells are still proliferating. Its supporting pediatric studies included children aged 4 to under 12 years and adolescents aged 12 to under 17 years; those study ages do not establish eligibility or expected benefit for a particular patient. The FDA approval review notes that diagnoses associated with biallelic RPE65 variants can differ, including LCA2 and RP20.
#1 Best Overall
- MEASUREMENTS: 4" MDF Wood Design - Lightweight yet durable ornament featuring professionally printed artwork that brings elegance to any holiday display
- VERSATILE DECORATION: Includes a festive red ribbon for traditional tree hanging, but also stands beautifully on mantels, shelves, or office desks year-round
- PREMIUM GIFT-READY QUALITY: Makes a thoughtful, personalized present that shows extra care compared to standard holiday gifts
- MEMORY MAKER: Perfect keepsake for commemorating special moments like Baby's First Christmas, weddings, anniversaries, or family milestones
- TIMELESS KEEPSAKE: Creates lasting holiday traditions as it's lovingly unpacked and displayed year after year, becoming part of your family's cherished memories
What did Argus II require?
Argus II was not simply a pair of goggles. It combined glasses with a video camera, an implanted retinal prosthesis, and other external equipment. The glasses captured images, but the system depended on an implant and clinical fitting, follow-up, and visual rehabilitation.
The FDA’s historical Humanitarian Device Exemption (HDE) indication described a narrow group of adults with retinitis pigmentosa (RP). The listed criteria were:
- Age 25 or older, with severe-to-profound RP.
- Bare or no light perception in both eyes, but a history of useful form vision.
- Aphakic or pseudophakic status (the natural lens is absent or has been replaced with an artificial lens).
- Ability to attend follow-up visits and complete device fitting and visual rehabilitation.
- For patients with no residual light perception, confirmed intact inner retinal function.
These are historical criteria, not a route to obtaining the device today. Cortigent says Argus II is no longer available; a company SEC filing says production and marketing were discontinued in 2019.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchHow the options differ
| Pathway | Who the regulatory or manufacturer information describes | Status |
|---|---|---|
| LUXTURNA | Confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells determined by the treating physician; not recommended under 12 months. | FDA-approved for this specific indication. |
| Argus II | Historical HDE criteria for a restricted group of adults with severe-to-profound RP; see the criteria above. | No longer available, according to Cortigent. |
| Orion | Cortigent describes a cortical prosthesis intended for profound blindness from several causes; the cited manufacturer information does not set out individual candidacy criteria. | Investigational and not FDA-approved, according to Cortigent. |
These approaches are not interchangeable. LUXTURNA targets a specific genetic cause and is delivered to the retina; Argus II was an implanted retinal-prosthesis system. Orion is a different, investigational cortical prosthesis, not an approved alternative to either one.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What to discuss with the care team
An ophthalmologist specializing in inherited retinal disease, together with a genetics professional, can assess whether the diagnosis, test results, eye findings, and treatment risks fit the relevant criteria. Useful questions include:
- Has clinical genetic testing found two disease-causing RPE65 variants, and how is the result interpreted?
- Does the examination show viable retinal cells, and what does that finding mean for candidacy?
- Could the diagnosis be one associated with biallelic RPE65 variants, such as LCA2 or RP20?
- For this patient, what are the expected benefits, surgical steps, and risks of LUXTURNA?
- If someone says “retinal prosthetic goggles,” are they referring to the discontinued Argus II system, an investigational device, or a nonmedical vision aid?
- What genetic counseling, low-vision services, and rehabilitation are available locally?
LUXTURNA risks to weigh
LUXTURNA is administered by subretinal injection. FDA’s approval review identifies serious risks including endophthalmitis (infection inside the eye), permanent decline in visual acuity, increased intraocular pressure, retinal tears or breaks, and cataract development or progression. The treating specialist should explain the current prescribing information and assess the risks and potential benefits for the individual.
Scope of this information
This article describes U.S. regulatory information current to October 9, 2026. It does not determine an individual’s eligibility or establish access or reimbursement outside the United States. Product labeling and availability can change, so patients should confirm current details with their care team.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
